Terminated PHASE1 INTERVENTIONAL 1-arm NCT01263366

Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients

Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy

Sponsor: ProCertus BioPharm, Inc

Updated 6 times since 2017 Last updated: Apr 17, 2013 Started: Jan 31, 2011 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Enrollment issues

This PHASE1 trial investigates Radiodermatitis and is currently terminated or withdrawn. ProCertus BioPharm, Inc leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ProCertus BioPharm, Inc
University of Wisconsin, Madison

Data source: ProCertus BioPharm, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States